UNSPSC 51102838: Clioquinol/hydrocortisone

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class DE250. This VA Drug Class (DE250) classifies this compound as belonging to the group ANTI-INFECTIVE/ANTI-INFLAMMATORY COMBINATIONS, TOPICAL.

UNSPSC 51102838 Clioquinol/hydrocortisone is a Commodity code with nominal scope in topical anti-inflammatory and antimicrobial pharmaceutical products, but recent state and local procurement activity under this code shows substantial mismatch with that definition. The actual solicitations tagged to this code span naloxone and drug deactivation systems (Seminole County, Florida), direct-to-manufacturer prescription programs (Texas Health and Human Services Commission), medical and first aid supplies for emergency response (City of Tampa), and multi-source generic pharmaceuticals and OTC products through cooperative purchasing (Minnesota Multistate Cooperative Purchasing Alliance). State and local governments procuring under this code are therefore buying a broad range of pharmaceutical products, emergency medical supplies, and pharmacy benefit program services rather than a single active ingredient formulation. Issuing bodies include county health departments, state health and human services agencies, municipal fire and rescue departments, and multi-state cooperative purchasing organizations serving public facilities across multiple jurisdictions.

Activity spans Florida, Texas, Minnesota, and Oregon, with procurement mechanisms ranging from sealed competitive bids (IFB) to requests for information (RFI) and requests for proposal (RFP). Representative recent solicitations include Seminole County's IFB 60459723LAS for 1,900 units of naloxone and 800 safe drug deactivation systems annually with a due date of July 26, 2023; the City of Tampa's IFB 26P00145 for 169 line items of medical and first aid supplies for the Tampa Fire Department Rescue Division due March 13, 2026, with an estimated contract value of $700,000.00 and a 5% bid discount set-aside for certified Small Local Business Enterprises; and the Minnesota Multistate Cooperative Purchasing Alliance's RFP S1070000015802 for generic multi-source pharmaceuticals and OTC products due March 26, 2026, distributed through authorized wholesalers to participating state and local government facilities across Minnesota and Oregon. The Texas HHS Commission's RFI HHS0017013 (posted April 3, 2026) represents early-stage market research into direct-to-manufacturer prescription programs rather than a formal procurement commitment.